Company Announcements

Block Listing Interim Review

Source: RNS
RNS Number : 8952J
Eco Animal Health Group PLC
29 April 2022
 

29 April 2022

 

 

ECO Animal Health Group PLC

 

BLOCK LISTING RETURN

 

Date: 29 April 2022

 

Name of applicant:

ECO Animal Health Group plc

Name of scheme:

Executive Share Option Scheme and Unapproved Share Option Scheme

Number and class of securities originally listed and the date of admission:

1,500,000 ordinary shares of 5 pence each on 20 July 2017

Period of return:

From:

1 May 2021

To:

29 April 2022

Balance of unallotted securities under scheme(s) from previous return:

393,005

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period:

17,500

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

375,505

 






 

For further information, please contact:

 

 

ECO Animal Health Group plc

David Hallas (CEO)

Christopher Wilks (CFO)

 


020 8447 8899

 

IFC Advisory

Graham Herring

Zach Cohen

 

020 3934 6630

 

Singer Capital Markets (Nominated Adviser & Joint Broker)

Mark Taylor

George Tzimas

 

020 7496 3000

Investec (Joint Broker)

Gary Clarence

Alex Penney

Carlo Spingardi

 

Peel Hunt LLP (Joint Broker)

Dr Christopher Golden

James Steel

020 7597 5970

 

 

 

 

020 7418 8900

 

Equity Developments

Hannah Crowe

Matt Evans

020 7065 2692

 

 

About ECO Animal Health

ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLREAELNALAAEFA